GlobeNewswire by notified

Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders


Lupin and Exeltis Announce Reimbursement Approval of NaMuscla® in Spain for the Symptomatic Treatment of Myotonia in Adults with non-dystrophic myotonic (NDM) Disorders
Agreement enables sustainable patient access of the only EU-approved treatment for myotonia symptoms
innon-dystrophic myotonic disorders

Mumbai, Zug, January 9, 2023: Global pharma major Lupin Limited (Lupin) and Exeltis Healthcare S.L (Exeltis) announced today that the Spanish Ministry of Health (MSCBC) has approved the reimbursement of Lupin’s NaMuscla® (mexiletine) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders on the National Health and Pharmacy Service. NaMuscla® is the first and only licensed product for this indication in Europe and will be commercialized by Lupin’s partner Exeltis in Spain.

NDM disorders are a group of rare, inherited neuromuscular disorders with an estimated prevalence of 1 case per 100,000 inhabitants in Spain1, and is characterized by the inability to relax muscles following voluntary contraction (myotonia). NaMuscla® reduces myotonia symptoms in people with NDM, resulting in a significant improvement in quality of life and other functional and clinical outcomes for patients2. NaMuscla®, which has been designated orphan drug status, received EU marketing authorization in December 20183.

“NDM patients in Spain will now be able to access NaMuscla® in a sustainable way. We are grateful to all stakeholders involved in the approval process, especially our partner Exeltis,” said Thierry Volle, President EMEA, Lupin. “Lupin’s transformational journey into specialty disease areas continues, with future investments planned for neuromuscular diseases, to meet the unmet needs of patients.”

"We are excited by this decision which will enable us to provide a new, innovative treatment option that addresses the unmet needs of patients with NDM as soon as possible," said Alberto Fábregas Gil, Director General Spain and Portugal, Exeltis. "This news allows us to distribute NaMuscla® quickly and effectively and strengthen our position in the central nervous system area."

To date, people in Spain living with NDM have had limited access to a licensed treatment for myotonia that can reduce the daily burden of this disabling, lifelong condition. Limited access leads to inconsistent medication supply, administrative challenges, and associated financial burdens. This, alongside limited clinical experience among healthcare professionals due to the rare nature of the disease, may result in significant harm to patients.

Lupin’s pediatric trial (NCT04624750), part of the pediatric investigation plan for NaMuscla® in children with myotonic disorders, is ongoing and successfully concluded patient enrolment in a first patient cohort group who were offered and rolled over into a 2-year follow-up study (NCT04622553). A post-authorization study to address long-term safety and treatment effects of NaMuscla® on patient-reported outcomes in adults with NDM (NCT04616807) has concluded patient enrollment and will provide 3 years prospective data on NaMuscla® in a real-life setting.

Notes for Editors

About Myotonic Disorders and Non-Dystrophic Myotonias (NDM)
Myotonic disorders are a group of heterogeneous, inherited, neuromuscular disorders characterized by a shared symptom called myotonia4. Myotonia can be described as an inability to relax a contraction of skeletal muscle which originates from a voluntary muscular contraction such as shaking someone’s hand and blinking, or everyday activities such as walking across a street and climbing stairs4.

Non-dystrophic myotonias (NDM) are a sub-set of rare (prevalence of 1:100,0001), inherited, myotonic disorders which are caused by mutations within ion channels in the sarcolemma membrane of skeletal muscles. Non-dystrophic myotonias exhibit both sodium and chloride channelopathies which result in altered membrane excitability5. For patients with NDM, myotonia is the most prominent symptom and demonstrates different phenotypes in subgroups of NDM disorders, and can affect different parts of the body, such as legs, arms, or facial muscles, more severely5.

Myotonia in patients with NDM has an onset in childhood and persists across their lifetime. Patients perceive that myotonia increases in severity over time, impacting daily life. Myotonia is described by patients in a variety of ways (stiffness, cramps, pain, difficulty releasing a fist, or difficulty swallowing or eating) which can contribute to substantial delays in diagnosis and treatment, leading to decreased patient quality-of-life and often significant disability4, 6.

About NaMuscla® (mexiletine)
NaMuscla® is the first and only antimyotonic agent licensed to treat symptomatic myotonia in adults with non-dystrophic myotonic disorders in Europe7. In randomized controlled trials, NaMuscla® (167 to 500 mg/day) has been shown to significantly reduce myotonia compared to placebo, reducing skeletal muscle hyperexcitability through its use-dependent, voltage-gated, sodium channel blocking actions which are independent of the cause of channel function. This resulted in an improvement in patient quality-of-life and other functional outcomes, with gastro-intestinal discomfort reported as the most common adverse event, demonstrating NaMuscla® to be safe and well tolerated2, 3, 7.

About Lupin
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 8.7% of its revenue in research and development in FY22.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a ‘Great Place to Work’ in the Biotechnology & Pharmaceuticals sector.

Please visit for more information.
Follow us on Twitter:|LinkedIn:

Contact for media inquiries:

Consilium Strategic Communications

Shweta Munjal
Vice President & Global Head – Corporate Communications

About Exeltis
Exeltis is a fast-growing division of the integrated health sciences group Insud Pharma. With a global footprint spanning over 40 countries, Exeltis has a team of more than 4,000 professionals supported by a global manufacturing network. It boasts a leadership position in the Women’s Health segment and in recent years, Exeltis has also diversified into Central Nervous System (CNS) and other therapeutic areas.


  1. Emery AEH, Neuromuscular Discord 1991;1:19-29
  1. Vicart S, et al. Neuromuscular Discord 2021;31:1124-1135
  2. NaMuscla®. Summary of Product Characteristics. EU/1/18/1325/001-004. 18 December 2018
  3. Stunnenberg, et al. Muscle Nerve 2020;62(4):430-444
  4. Matthews E, et al. Brain 2010;133:9–22
  5. Trivedi JR, et al. Brain 2013;136:2189-200
  6. Matthews E, et al. Pract Neurol 2021;0:1–10

Job Code: EU-NAM-2301-00001

To view this piece of content from, please give your consent at the top of this page.
To view this piece of content from, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Aktia Bank Abp riktar vederlagsfri aktie-emission till bolaget själv30.1.2023 16:30:00 CET | Pressemelding

Aktia Bank Abp Börsmeddelande 30.1.2023 kl. 17.30 Aktia Bank Abp riktar vederlagsfri aktie-emission till bolaget själv Aktia Bank Abp:s styrelse har idag, med stöd av det av ordinarie bolagsstämman 6.4.2022 beviljade aktie-emissionsbemyndigandet, beslutat att vederlagsfritt emittera 80 000 nya aktier till bolaget själv. De emitterade aktierna kommer att användas för utbetalning av ersättningar i enlighet med bolagets aktiebelöningsprogram. Efter emissionen är bolagets totala antal aktier 72 465 072 aktier, varav 268 726 aktier är i bolagets besittning. De nya aktierna registreras i handelsregistret uppskattningsvis 13.2.2023, varefter bolaget utan dröjsmål kommer att ansöka om att de nya aktierna upptas till offentlig handel på Nasdaq Helsinki Oy:s börslista tillsammans med bolagets befintliga aktier. Aktia Bank Abp Mera information: Ari Syrjäläinen, koncernjurist, tfn 010 247 6350 Distribution: Nasdaq Helsinki Oy Massmedier Aktia är en finländsk kapitalförvaltare, bank o

Aktia Bank Plc directs share issue to the company itself without payment30.1.2023 16:30:00 CET | Press release

Aktia Bank Plc Stock Exchange Release 30 January 2023 at 5.30 p.m Aktia Bank Plc directs share issue to the company itself without payment The Board of Directors of Aktia Bank Plc has today, pursuant to the share issue authorization granted by the Annual General Meeting held on 6 April 2022, resolved on an issue of 80,000 new shares to the company itself without payment. The new shares to be issued to the company will be used for reward payments under the company's incentive programs. The total number of the company's shares after the share issue is 72,465,072 shares, of which 268,726 shares in total are held by the company. The new shares will be registered with the Finnish Trade Register on or about 13 February 2023 after which the company without delay will apply for the admission of the new shares to public trading alongside the company's existing shares on the official list of Nasdaq Helsinki Ltd. Aktia Bank Plc For more information: Ari Syrjäläinen, General Counsel, tel. +358 10

Aktia Bank Abp:s incitamentsprogram 2023–202430.1.2023 16:30:00 CET | Pressemelding

Aktia Bank Abp Börsmeddelande 30.1.2023 kl. 17.30 Aktia Bank Abp:s incitamentsprogram 2023–2024 Aktiesparprogrammet Aktia Bank Abp:s styrelse har beslutat om att fortsätta det långsiktiga aktiesparprogrammet för Aktiakoncernens anställda, AktiaUna, som introducerades 2018 för att stödja genomförandet av Aktias strategi. Syftet med aktiesparprogrammet är att uppmuntra Aktias anställda att investera i samt äga bolagets aktier. Syftet är också att likrikta de anställdas och ledningens intressen och engagemang för ett långsiktigt arbete och en god värdeutveckling samt ett växande aktieägarvärde. AktiaUna aktiesparprogrammet gör det möjligt för Aktias cirka 900 anställda att spara 2–4 % av sin lön (ledningsgruppsmedlemmarna upp till 12 % och utvalda nyckelpersoner upp till 7 %) och med sparsumman regelbundet förvärva Aktia-aktier med 10 procents rabatt. Deltagarna uppmuntras ytterligare genom att efter cirka 2 år ge dem vederlagsfria tilläggsaktier för förvärvade aktier inom ramen för aktie

Aktia Bank Plc’s Incentive Plans 2023–202430.1.2023 16:30:00 CET | Press release

Aktia Bank Plc Stock Exchange Release 30 January 2023 at 5.30 p.m. Aktia Bank Plc’s Incentive Plans 2023–2024 Share Savings Plan The Board of Directors of Aktia Bank Plc has decided on a continuation of AktiaUna, a long-term share savings plan for the employees of the Aktia Group, that was launched in 2018 to support the implementation of Aktia’s strategy. The objective of the share savings plan is to motivate Aktia’s employees to invest in Aktia shares and to own shares in Aktia. The objective is also to align the interests and commitment of the employees and management to work for a good value development and increased shareholder value in the long-term. AktiaUna share savings plan offers approximately 900 Aktia employees the opportunity to save 2–4% of their salaries (the members of the Group’s Executive Committee up to 12% and selected key employees up to 7%) and with this savings amount regularly acquire Aktia shares at a 10% discount. Furthermore, the participants are motivated b

Transactions in connection with share buyback programme30.1.2023 16:17:04 CET | Press release

On 9 February 2022, Pandora announced a new share buyback programme, cf. Company announcement no. 692. The share buyback programme is executed in accordance with Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation). The purpose of the programme is to reduce Pandora’s share capital and to meet obligations arising from company incentive programmes. Under the programme Pandora will repurchase shares for an aggregate maximum amount of DKK 3.3 billion. The programme commenced on 9 February 2022, cf. Company Announcement no. 692, and will conclude no later than 3 February 2023. The following transactions have been made under the programme: Number of sharesAverage purchase price, DKKTransaction value, DKKAccumulated under the programme 6,140,0673,141,087,890 23 January 2022 28,554 566.63 16,179,673 24 January 2022 25,930 576.32 14,943,879 25 January 2022 27,884 570.43 15,905,957 26 January 2022 28,409 574.72 16,32